Gemcitabine in bone sarcoma resistant to doxorubicin-based chemotherapy

By Merimsky Ofer   Meller Isaac   Kollender Yehuda   Issakov Josephine   Flusser Gideon   Inbar Moshe  

Sarcoma, Vol. 4, Iss. 1-2, 2000-03 ,pp. : 7-10

Informa Healthcare

Access to resources Recommend Favorite

Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience

By He Aina  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 498-505

Springer Publishing Company

Access to resources Recommend Favorite

Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

By            

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2567-2571

Spandidos Publications

Access to resources Recommend Favorite

The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers

By Matsui Yoshiyuki  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 321-328

Springer Publishing Company

Access to resources Recommend Favorite

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

By                                                

Oncology Letters, Vol. 4, Iss. 6, 2012-01 ,pp. : 1281-1284

Spandidos Publications

Access to resources Recommend Favorite